InnoCare Pharma Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 9969.HK | 6IB.F | GMAB | ROIV | 2162.HK | SMZ1.F | |
|---|---|---|---|---|---|---|
| Market cap | 21.56B | 17.27B | 33.89B | 27.61B | 20.67B | 11.09B |
| P/E (TTM) | 20.3 | 123.8 | 43.4 | — | 23.8 | 31.2 |
| Forward P/E | 53.2 | — | 34.9 | -27.5 | 206.8 | — |
| Price/book | 1.9 | 6.2 | 5.5 | 6.5 | 4.4 | 2.6 |
| Dividend yield | — | — | — | — | — | 2.90% |
| 1-year change | −14.61% | −1.76% | +91.12% | +85.85% | +8.65% | −23.60% |
| Today | +1.33% | +3.42% | −0.72% | +6.08% | +2.48% | +1.45% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 9969.HK news ›InnoCare Pharma Ltd. (9969) Receives a Buy from Guotai Haitong
Guotai Haitong analyst maintained a Buy rating on InnoCare Pharma Ltd. yesterday and set a price target of HK$19.31. InnoCare Pharma Ltd. has ... Guotai Haitong analyst maintained a Buy rating on InnoCare Pharma Ltd. yesterday and set a…
CMB International Securities Sticks to Its Buy Rating for InnoCare Pharma Ltd. (9969)
In a report released yesterday, from CMB International Securities maintained a Buy rating on InnoCare Pharma Ltd., with a price target of HK$18... In a report released yesterday, from CMB International Securities maintained a Buy rating on…
InnoCare Pharma gains Chinese IND approval for dual-target IBD antibody ICP‑B161
ICP-B161 is the company's fifth candidate to enter clinical development in 2026; the release gives no enrollment timetable. Clinical development can advance after InnoCare Pharma HKG9969 SHA688428 reported Chinese IND approval for its…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com2
- mugglehead.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.